Profile data is unavailable for this security.
About the company
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2018
- Employees72.00
- LocationBoundless Bio Inc9880 Campus Point Drive, Suite 120SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 766-9912
- Fax+1 (302) 655-5049
- Websitehttps://boundlessbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 188.82m | 75.00 | -- | 2.61 | -- | 23.59 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Greenwich Lifesciences Inc | 0.00 | -9.24m | 191.01m | 3.00 | -- | 37.29 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 194.00m | 32.00 | -- | 1.24 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 194.46m | 112.00 | -- | -- | -- | 8.85 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Zevra Therapeutics Inc | 28.01m | -50.90m | 194.62m | 65.00 | -- | 3.99 | -- | 6.95 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Omeros Corp | 0.00 | -179.09m | 194.69m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Scilex Holding Co | 47.05m | -160.60m | 195.69m | 106.00 | -- | -- | -- | 4.16 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Boundless Bio Inc | -100.00bn | -100.00bn | 202.96m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Chromadex Corp | 83.17m | -3.53m | 208.49m | 106.00 | -- | 7.16 | -- | 2.51 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Coherus Biosciences Inc | 301.87m | -59.29m | 208.80m | 249.00 | -- | -- | -- | 0.6917 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Prelude Therapeutics Inc | 0.00 | -125.55m | 211.48m | 128.00 | -- | 1.00 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Generation Bio Co | 9.96m | -169.06m | 211.56m | 174.00 | -- | 1.60 | -- | 21.23 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Ovid Therapeutics Inc | 473.53k | -50.68m | 217.09m | 40.00 | -- | 2.77 | -- | 458.45 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 217.44m | 274.00 | -- | 1.05 | -- | 3.05 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.26m | 14.67% |
RA Capital Management LPas of 02 Apr 2024 | 2.18m | 9.81% |
Redmile Group LLCas of 31 Mar 2024 | 1.11m | 5.01% |
Sectoral Asset Management, Inc.as of 31 Mar 2024 | 855.88k | 3.85% |
Citadel Advisors LLCas of 31 Mar 2024 | 853.53k | 3.84% |
Wellington Management Co. LLPas of 02 Apr 2024 | 556.23k | 2.50% |
Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 375.00k | 1.69% |
Federated Global Investment Management Corp.as of 31 Mar 2024 | 375.00k | 1.69% |
SilverArc Capital Management LLCas of 31 Mar 2024 | 312.50k | 1.41% |
Alyeska Investment Group LPas of 31 Mar 2024 | 250.00k | 1.12% |